<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20227" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cytarabine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Faruqi</surname>
            <given-names>Arjumand</given-names>
          </name>
          <aff>King George&#x02019;s Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arjumand Faruqi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20227.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cytarabine is a medication used in the management and treatment of leukemias and lymphomas. It belongs to the antimetabolic group of medications. This activity reviews the indications, action, and contraindications for cytarabine as a valuable agent in treating acute myeloid leukemia (and other leukemias). This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with leukemia and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of cytarabine.</p></list-item><list-item><p>Describe the potential adverse effects of cytarabine.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving therapy with cytarabine.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination for patient safety in cases of cytarabine overdose and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20227&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20227">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20227.s2" sec-type="Indications">
        <title>Indications</title>
        <p>In the early 1950s, researchers discovered cytarabine as a nucleoside (containing arabinose sugar) in&#x000a0;<italic toggle="yes">Cryptotethia crypta, </italic>a species of sponges<italic toggle="yes">.&#x000a0;</italic>Cytarabine is an&#x000a0;antimetabolite and an antineoplastic agent that belongs to the category of drugs known as anthracyclines.&#x000a0;</p>
        <p>Cytarabine has both labeled and off-labeled indications.<bold>&#x000a0;</bold>Labeled indications of cytarabine include the treatment of acute lymphoblastic leukemia, remission induction therapy in acute myeloid leukemia in adult and pediatric patients, the treatment of chronic myeloid leukemia (blast phase), and prophylaxis and treatment of meningeal leukemia.&#x000a0;Some of the many&#x000a0;off-labeled indications&#x000a0;of cytarabine in adults&#x000a0;include refractory chronic lymphocytic leukemia and refractory or relapsed Hodgkin disease. It is also an option for non-Hodgkin&#x02019;s lymphoma and primary central nervous system (CNS) lymphoma.</p>
      </sec>
      <sec id="article-20227.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cytarabine is a pyrimidine analog and is also known as arabinosylcytosine (ARA-C). It is converted into the triphosphate form within the cell and competes with cytidine to incorporate itself into the DNA. The sugar moiety of cytarabine hinders the rotation of the molecule within the DNA. The process of DNA replication ceases, specifically during the S phase of the cell cycle, making it a specific drug for rapidly dividing cells, such as those seen in cancer. DNA replication and repair also halts due to the inhibition of DNA polymerase by cytarabine. This drug must act for a time equivalent to one cell cycle to effectively inhibit the replication of tumor cells. Hence the bolus dose of cytarabine is given every 8&#x000a0;to 12 hours to maintain optimum intracellular levels.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The absorption of cytarabine is not effective when taken orally due to high first-pass metabolism. When administered subcutaneously, intrathecally, or intravenously, it has a high bioavailability. It has a low plasma protein binding capacity and, thus, a high volume of distribution. It can cross the blood-brain barrier and hence has an off-label use in primary CNS lymphomas. Cytarabine metabolism primarily occurs in the liver. It has an active metabolite- azacytidine triphosphate; and an inactive metabolite- uracil arabinoside, which is cleared by the kidney.</p>
      </sec>
      <sec id="article-20227.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Solution, Injection: 10 mg/ml, 20 mg/mL (25 mL), 100 mg/ml</p>
          </list-item>
          <list-item>
            <p>Intrathecal injection, liposomal: 50 mg/5ml</p>
          </list-item>
        </list>
        <p><bold>Administration&#x000a0;</bold>- Rapid intravenous infusion, infuse over 1&#x000a0;to 3 hours intravenously or subcutaneously or intrathecally.&#x000a0;</p>
        <p><bold>Storage&#x000a0;</bold>- Store at room temperature.&#x000a0;</p>
        <p>
<bold>Dosing: Adult</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Acute lymphoblastic leukemia (off-label dosing):
<list list-type="bullet"><list-item><p>Induction regimen, relapsed or refractory- Administer 3,000 mg/sq.meter of cytarabine over 3 hours by intravenous infusion daily for five days in combination with idarubicin for three days.<xref ref-type="bibr" rid="article-20227.r1">[1]</xref></p></list-item><list-item><p>Dose-intensive regimen- 3,000 mg/sq.meter of cytarabine over 2 hours by intravenous infusion. This dose is to be given every 12 hours on days 2 and 3 (4 doses/cycle) of even-numbered cycles in combination with methotrexate.<xref ref-type="bibr" rid="article-20227.r2">[2]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Acute myeloid leukemia (remission induction chemotherapy):
<list list-type="bullet"><list-item><p>Administer standard dose 100 mg/sq.meter/day of cytarabine by continuous intravenous infusion for 7 days or give 200 mg/sq.meter/day by continuous intravenous infusion for 7 days(as 100 mg/m2 over 12 hours every 12 hours).<xref ref-type="bibr" rid="article-20227.r3">[3]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Acute myeloid leukemia consolidation therapy (off-label use):
<list list-type="bullet"><list-item><p>5+2 regimen: Administer 100 mg/sq.meter/day of cytarabine for five days by intravenous infusion in combination with daunorubicin or idarubicin, or mitoxantrone.<xref ref-type="bibr" rid="article-20227.r3">[3]</xref><xref ref-type="bibr" rid="article-20227.r4">[4]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Acute myeloid leukemia salvage treatment (off-label use):
<list list-type="bullet"><list-item><p>CLAG-M regimen: Administer 2,000 mg/sq.meter/day of cytarabine by intravenous infusion over 4 hours for five days in combination with cladribine, G-CSF, and mitoxantrone.<xref ref-type="bibr" rid="article-20227.r5">[5]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Acute promyelocytic leukemia consolidation therapy (off-label use):
<list list-type="bullet"><list-item><p>First consolidation course: Administer 200 mg/sq.meter/day of cytarabine by intravenous infusion for seven days in combination with daunorubicin.<xref ref-type="bibr" rid="article-20227.r6">[6]</xref></p></list-item><list-item><p>Second consolidation course:
<list list-type="bullet"><list-item><p>If age is &#x02264;60 years and low risk (WBC &#x0003c;10,000/cubic mm), then administer 1,000 mg/sq.meter of cytarabine every 12 hours for four days (8 doses) by intravenous infusion.</p></list-item><list-item><p>If age is &#x0003c;50 years and high risk (WBC &#x02265;10,000/cubic mm), then administer 2,000 mg/sq.meter of cytarabine every 12 hours for five days (10 doses) by intravenous infusion.</p></list-item><list-item><p>If age is 50 to 60 years and high risk (WBC &#x02265;10,000/cubic mm), then administer 1500 mg/sq.meter of cytarabine every 12 hours for five days (10 doses) by intravenous infusion.</p></list-item><list-item><p>If age is &#x0003e;60 years and high risk (WBC &#x02265;10,000/cubic mm) then administer 1,000 mg/sq.meter every 12 hours for four days (8 doses) by intravenous infusion.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Acute promyelocytic leukemia induction (off-label dosing):
<list list-type="bullet"><list-item><p>Administer 200 mg/sq.meter/day of cytarabine by continuous intravenous infusion for seven days, beginning on the third day of treatment in combination with tretinoin and daunorubicin.<xref ref-type="bibr" rid="article-20227.r6">[6]</xref><xref ref-type="bibr" rid="article-20227.r7">[7]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20227.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Myelosuppression is the most dreaded adverse effect of cytarabine and can present as acute and severe pancytopenia with striking megaloblastic changes.<xref ref-type="bibr" rid="article-20227.r8">[8]</xref>&#x000a0;Other, less life-threatening symptoms include irritation at the site of administration, gastrointestinal disturbances, stomatitis, conjunctivitis, reversible hepatic enzyme elevation, and dermatitis. Severe hypersensitivity, such as anaphylaxis, occurs on rare occasions but is a strong indication for discontinuation of cytarabine therapy. Cerebral and cerebellar toxicity may follow an intrathecal administration of cytarabine. Manifestations of cerebellar toxicity include ataxia and slurred speech, while that of cerebral toxicity are seizures and dementia.<xref ref-type="bibr" rid="article-20227.r9">[9]</xref><xref ref-type="bibr" rid="article-20227.r10">[10]</xref>&#x000a0;</p>
        <p>Cytarabine might affect the cardiovascular system also, causing angina pectoris and even pericarditis. Cytarabine syndrome is a rare illness produced shortly after administration of cytarabine, characterized by non-specific symptoms like fever, malaise, rash, joint pain, and muscle pain, and is manageable with corticosteroids. Severe symptoms tend to occur more commonly in patients with renal impairment as the renal clearance of the drug decreases.</p>
      </sec>
      <sec id="article-20227.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cytarabine is contraindicated in patients who have had a hypersensitivity reaction to it or any of the fundamental ingredients used in the preparation of the drug. With active meningeal infections, liposomal cytarabine is also contraindicated.</p>
      </sec>
      <sec id="article-20227.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>As cytarabine affects various organs, a panel of tests is necessary to monitor the patients. These are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver function tests</p>
          </list-item>
          <list-item>
            <p>Complete blood count</p>
          </list-item>
          <list-item>
            <p>Differential WBC count</p>
          </list-item>
          <list-item>
            <p>Platelet count</p>
          </list-item>
          <list-item>
            <p>Serum creatinine</p>
          </list-item>
          <list-item>
            <p>Blood urea nitrogen (BUN)</p>
          </list-item>
          <list-item>
            <p>Serum uric acid</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20227.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity caused by cytarabine can classify into either low dose or high dose toxicity. The only noteworthy low-dose toxicity is myelosuppression, while corneal toxicity is frequent with high doses of cytarabine. Continuous infusion may prove more toxic than the typical intermittent dosage. Considerable cardiac toxicity has been observed only in the standard induction schedules.<xref ref-type="bibr" rid="article-20227.r11">[11]</xref></p>
      </sec>
      <sec id="article-20227.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>It is an observation that in delivering therapeutic drugs, incorrect doses of drugs are sometimes administered.<xref ref-type="bibr" rid="article-20227.r12">[12]</xref>&#x000a0;Lack of proper care during intrathecal administration of cytarabine in pediatric patients can lead to overdose. Previously cerebrospinal fluid exchange was recommended if such an incident occurred. Contrary to this belief, there have been recent reports that if there is prompt identification of such an error, then management&#x000a0;via a cerebrospinal fluid exchange is not necessary.<xref ref-type="bibr" rid="article-20227.r13">[13]</xref><xref ref-type="bibr" rid="article-20227.r14">[14]</xref>&#x000a0;In the above case reports, hydrocortisone was administered, and the patient received adequate supportive care. All patients were neurologically stable at the time of overdose. They did not show any signs of cytarabine toxicity or complications and quickly recovered.</p>
        <p>Given the critical nature of the illnesses for which cytarabine is given, an interprofessional, coordinated team approach to therapy and monitoring is absolutely essential. This team includes specialists, mid-level practitioners, family clinicians, oncology specialty-trained nurses, and pharmacists, preferably with oncology specialization. By working collaboratively and engaging in open information-sharing regarding the latest information on the patient's case, patient outcomes can be optimized, and adverse events minimized when utilizing cytarabine therapy. [Level 5]</p>
      </sec>
      <sec id="article-20227.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20227&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20227">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20227/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20227">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20227.s11">
        <title>References</title>
        <ref id="article-20227.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Aliff</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Frankel</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kalaycio</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Maslak</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Jurcic</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Scheinberg</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Roma</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.</article-title>
            <source>Cancer</source>
            <year>2002</year>
            <month>Aug</month>
            <day>01</day>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>581</fpage>
            <page-range>581-7</page-range>
            <pub-id pub-id-type="pmid">12209751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Beran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Andreeff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freireich</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.</article-title>
            <source>J Clin Oncol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>547</fpage>
            <page-range>547-61</page-range>
            <pub-id pub-id-type="pmid">10653870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiernik</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Arlin</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Periman</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ritch</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Enck</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Weitberg</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.</article-title>
            <source>Blood</source>
            <year>1992</year>
            <month>Jan</month>
            <day>15</day>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-9</page-range>
            <pub-id pub-id-type="pmid">1730080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arlin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiernik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saletan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cartwright</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.</article-title>
            <source>Leukemia</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-83</page-range>
            <pub-id pub-id-type="pmid">2179638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wierzbowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pluta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wawrzyniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cebula</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ho&#x00142;owiecki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kyrcz-Krzemie&#x00144;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grosicki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giebel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skotnicki</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Piatkowska-Jakubas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuliczkowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kie&#x00142;bi&#x00144;ski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zawilska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>K&#x00142;oczko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wrzesie&#x00144;-Ku&#x0015b;</surname>
                <given-names>A</given-names>
              </name>
              <collab>Polish Adult Leukemia Group</collab>
            </person-group>
            <article-title>Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.</article-title>
            <source>Eur J Haematol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-26</page-range>
            <pub-id pub-id-type="pmid">18076637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ad&#x000e8;s</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chevret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chevallier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Raffoux</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vellenga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guerci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pigneux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huguet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rayon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stoppa</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>de la Serna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cahn</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Meyer-Monard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>de Botton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bergua</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lamy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vekhoff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ifrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dombret</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ferrant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Degos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fenaux</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Feb</month>
            <day>01</day>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>1078</fpage>
            <page-range>1078-84</page-range>
            <pub-id pub-id-type="pmid">17975017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powell</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Willman</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feusner</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Couban</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Nov</month>
            <day>11</day>
            <volume>116</volume>
            <issue>19</issue>
            <fpage>3751</fpage>
            <page-range>3751-7</page-range>
            <pub-id pub-id-type="pmid">20705755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCarthy</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Cell type and conduction velocity of rat primary sensory neurons with calcitonin gene-related peptide-like immunoreactivity.</article-title>
            <source>Neuroscience</source>
            <year>1990</year>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>623</fpage>
            <page-range>623-32</page-range>
            <pub-id pub-id-type="pmid">2352644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Royer</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Cytarabine and neurologic toxicity.</article-title>
            <source>J Clin Oncol</source>
            <year>1991</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>679</fpage>
            <page-range>679-93</page-range>
            <pub-id pub-id-type="pmid">1648599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sainz de la Maza Cantero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez Mart&#x000ed;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Felipe Mimbrera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corral Corral</surname>
                <given-names>&#x000cd;</given-names>
              </name>
            </person-group>
            <article-title>Cerebellar toxicity due to cytarabine: A series of 4 cases.</article-title>
            <source>Neurologia</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>491</fpage>
            <page-range>491-2</page-range>
            <pub-id pub-id-type="pmid">25728956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stentoft</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The toxicity of cytarabine.</article-title>
            <source>Drug Saf</source>
            <year>1990</year>
            <season>Jan-Feb</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-27</page-range>
            <pub-id pub-id-type="pmid">2178634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Veen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van den Bemt</surname>
                <given-names>PMLA</given-names>
              </name>
              <name>
                <surname>Wouters</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Twisk</surname>
                <given-names>JWR</given-names>
              </name>
              <name>
                <surname>de Gier</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Taxis</surname>
                <given-names>K</given-names>
              </name>
              <collab>BCMA Study Group</collab>
              <name>
                <surname>Duyvendak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luttikhuis</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>JJW</given-names>
              </name>
              <name>
                <surname>Vasbinder</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Atrafi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brasse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mangelaars</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Association between workarounds and medication administration errors in bar-code-assisted medication administration in hospitals.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-392</page-range>
            <pub-id pub-id-type="pmid">29025037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Omar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amayiri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Madanat</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Safety of inadvertent administration of overdose of intrathecal Cytarabine in a pediatric patient.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>384</fpage>
            <page-range>384-7</page-range>
            <pub-id pub-id-type="pmid">24781453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20227.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thienprayoon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heym</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Pelfrey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Accidental overdose of intrathecal cytarabine in children.</article-title>
            <source>Ann Pharmacother</source>
            <year>2013</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>e24</fpage>
            <pub-id pub-id-type="pmid">23606548</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
